Vladimir Coric, MD

2024

• Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies

  Dickson S, Mallinckrodt C, Rogula B, Powell L, Potashman M, Coric V, L’Italien G, Hendrix S. Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies. Neurology And Therapy 2024, 1-13. PMID: 39287752, DOI: 10.1007/s40120-024-00661-2.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg‐AD mice

  Pfitzer J, Pinky P, Perman S, Redmon E, Cmelak L, Suppiramaniam V, Coric V, Qureshi I, Gramlich M, Reed M. Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg‐AD mice. Journal Of Neurochemistry 2024 PMID: 39214859, DOI: 10.1111/jnc.16215.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  Concepts

• Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis

  L’Italien G, Oikonomou E, Khera R, Potashman M, Beiner M, Maclaine G, Schmahmann J, Perlman S, Coric V. Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis. Neurology And Therapy 2024, 13: 1287-1301. PMID: 38814532, PMCID: PMC11263303, DOI: 10.1007/s40120-024-00625-6.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012)

  Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, Crimin K, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Hendrix S, L’Italien G. Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204570.

  Peer-Reviewed Original Research

• Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007)

  Berg A, Lerner J, Millichap J, L’Italien G, Coric V, Potashman M. Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204827.

  Peer-Reviewed Original Research

• Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018)

  Potashman M, Popoff E, Powell L, Beiner M, Mackenzie A, Coric V, Schmahmann J, L’Italien G. Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204549.

  Peer-Reviewed Original Research

• Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data (S2.004)

  L’Italien G, Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, Crimin K, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Hendrix S. Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data (S2.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204569.

  Peer-Reviewed Original Research

  Concepts

• Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects (S5.006)

  Sevinsky H, Rozakis R, Nepomuceno T, Malatesta J, Awsare B, Ashbrenner E, Kaplita S, Gentile K, Hussey E, Qureshi I, Coric V, Bertz R. Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects (S5.006). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205022.

  Peer-Reviewed Original Research

  Concepts

• No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole (P4-4.014)

  Bertz R, Rozakis R, Donohue M, Sevinsky H, Awsare B, Kaplita S, Hussey E, Qureshi I, Coric V. No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole (P4-4.014). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206134.

  Peer-Reviewed Original Research

  Concepts

• Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders (P4-4.013)

  Qureshi I, Beiner M, Bertz R, Kaplita S, Yang R, Munivar A, Stock D, Wirtz V, Coric V. Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders (P4-4.013). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206182.

  Peer-Reviewed Original Research